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Abstract

The nanoprecipitate method was utilized to form a drug polymer complex.
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The FTIR data shown in the results section demonstrates that the drug
polymer complex was successfully produced. In the figure, the FTIR
results of the drug- Silymarin is shown in blue. The polymer used is PLGA
resomer 502H which is shown as the gray line in the graph. PLGA is
composed of carboxylic groups, ester groups and methyl groups which can
all be seen in the data. The stabilizer which is Polyvinyl Alcohol (PVA) is
represented in yellow. The structures of each compound are shown below.
The complex is shown in orange and demonstrates all the necessary peaks
which correspond to the drug, polymer and stabilizer. From this we can
conclude that the complex was successfully produced using the
nanoprecipitate method.

The organic phase was added to the aqueous phase and homogenized, followed
by a period of stirring to remove the solvent.
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Figure 1. (a) Effects of Crohn’s Disease & Ulcerative Colitis on GI
Tract (b) Scope view of IBD
Crohn’s Disease and Ulcerative Colitis
Ø Cramps, Abdominal Pain
are
cumulatively
known
as
Ø Blood in stool
Inflammatory Bowel Disease (IBD),
Ø Diarrhea, Constipation, bloating
they are distinguished by inflammation
Ø Visceral Hypersensitivity
in the gastrointestinal tract. A survey
Ø Fever, fatigue
from 2017 stated that 57% of IBD
Ø Unintended weight loss
patients were originally misdiagnosed,
Ø Intestinal Inflammation
since the symptoms can suggest many
things.1 Symptoms include2
As stated by Nature Reviews Gastroenterology & Hepatology, more than
one million people in the United states and over two and a half million
people in Europe are presumed to have IBD.3
Ø Since the twentieth century, Ulcerative Colitis and Crohn’s Disease
has significantly increased in the western world.
Ø The prevalence in the Western world has now increased to 0.5% of the
entire population.4
Ø Recently, IBD has evolved into a global disease and its prevalence in
every continent continues to grow exponentially.

Objectives
Ø To develop a stable PLGA drug polymer complex.
Ø To compare the PLGA complex to a S100 drug polymer complex.

Drug: Silymarin, Polymer: PLGA 502H, 1:4 Formation of precipitate
after centrifuge.
Solvents: Ethyl Acetate 7:3 Stabilizer: PVA

Results

PLGA 502H Structure
Based on scientific literature, IBD is a chronic disease that does not have
any treatments without considerable side effects. The purpose of the
proposed drug polymer complex pH sensitive delivery system is to
reduce inflammation of the GI tract in Ulcerative Colitis and Crohn’s
Disease. The complex formulation has been shown using the
nanoprecipitation method with specific drug, polymers and stabilizer.

Future Outlook
In future experimentation, this project contains optimizing the drug
release from the polymer using the pH dissolution test, drug loading,
drug coatings at a range of different pH of the GI tract for release at
specific times, and mice studies.
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This figure shows the results obtained from taking an FTIR of the drug, polymer,
stabilizer as well and complex.
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